title: Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
abstract: Increased galectin-3 expression has been currently showed to be associated with poor prognosis in some hematological malignancies, such as acute myeloid leukemia, diffuse large B cell lymphoma. However, little is known about the clinical significance of galectin-3 in patients with acute promyelocytic leukemia (APL). We investigated the concentration of serum galectin-3 and characterized the relationship between galectin-3 and outcome in patients with APL. Higher galectin-3 levels were detected in patients with APL compared with the healthy controls (p < 0.001). Higher galectin-3 levels were closely associated with older ages (p < 0.001), the medical history of psoriasis (p = 0.036), coagulopathy (p = 0.042), and CD34 expression (p = 0.004). Compared with patients with lower galectin-3 levels, those with higher galectin-3 levels had significant shorter overall survival (p = 0.028) and relapse-free survival (p = 0.001). Multivariate analysis showed that serum galectin-3 was an independent unfavorable factor for relapse-free survival in patients with APL treated with all-trans retinoic acid and arsenic trioxide-based frontline therapy. Clinical impact of galectin-3 should be further investigated in patients with APL.
authors.affiliation: Department of hematology, Binzhou Medical University Hospital, Binzhou, Shandong, China. gn2882155@163.com.
authors.forename: Na
authors.initials: N
authors.lastname: Gao
authors.affiliation: Department of hematology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
authors.forename: Xue-Xia
authors.initials: XX
authors.lastname: Wang
authors.affiliation: Department of hematology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
authors.forename: Jian-Rong
authors.initials: JR
authors.lastname: Sun
authors.affiliation: Department of hematology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
authors.forename: Wen-Zheng
authors.initials: WZ
authors.lastname: Yu
authors.affiliation: Department of nephrology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
authors.forename: Xi-Zhi
authors.initials: XZ
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage; D014408:Biomarkers, Tumor; D016022:Case-Control Studies; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D005260:Female; D037502:Galectin 3 / Q000097:blood*; D006801:Humans; D016130:Immunophenotyping; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D010087:Oxides / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D014178:Translocation, Genetic; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D001152:Arsenicals; D014408:Biomarkers, Tumor; D037502:Galectin 3; D015514:Oncogene Proteins, Fusion; D010087:Oxides; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin; D000077237:Arsenic Trioxide
keywords: Acute promyelocytic leukemia; Galectin-3; Overall survival; Prognosis; Relapse